Malaysia vs Thailand: Average cost of multi drug-resistant tuberculosis treatment
Malaysia
2,000 constant 2022 US$
in 2024
Thailand
1,823 constant 2022 US$
in 2024
Malaysia rank
22nd
Thailand rank
25th
Average cost of multi drug-resistant tuberculosis treatment over time
- Malaysia
- Thailand
How they compare
Malaysia currently reports 2,000 constant 2022 US$ against 1,823 constant 2022 US$ in Thailand, a difference of 177 constant 2022 US$.
That makes Malaysia's figure about 1.1 times Thailand's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Thailand ahead.
Malaysia ranks 22nd and Thailand ranks 25th of 92 countries.
Thailand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malaysia | Thailand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,000 constant 2022 US$ | 3,461 constant 2022 US$ | 1,461 constant 2022 US$ | Thailand |
| 2020s | 2,000 constant 2022 US$ | 2,196 constant 2022 US$ | 195.8 constant 2022 US$ | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Malaysia or Thailand?
- Malaysia, at 2,000 constant 2022 US$ against 1,823 constant 2022 US$ in Thailand as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Malaysia and Thailand?
- 177 constant 2022 US$, with Malaysia ahead.
- How many years of comparable data are there for Malaysia and Thailand?
- 8 years are reported by both, from 2017 to 2024.
- How do Malaysia and Thailand rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Malaysia ranks 22nd and Thailand ranks 25th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.